| 32.22 -3.02 (-8.57%) | 09-24 13:21 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.78 |
1-year : | 54.53 |
| Resists | First : | 40.91 |
Second : | 46.68 |
| Pivot price | 35.96 |
|||
| Supports | First : | 31.56 |
Second : | 26.26 |
| MAs | MA(5) : | 33.99 |
MA(20) : | 37.37 |
| MA(100) : | 39.25 |
MA(250) : | 30.79  |
|
| MACD | MACD : | -1.8 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 15.3 |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 57.13 | Low : | 14.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NBTX ] has closed above bottom band by 2.2%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.85 - 35.99 | 35.99 - 36.13 |
| Low: | 34.37 - 34.53 | 34.53 - 34.7 |
| Close: | 34.97 - 35.23 | 35.23 - 35.48 |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Tue, 22 Sep 2026
Nanobiotix (Nasdaq: NBTX) details August 2026 share and voting rights totals - Stock Titan
Thu, 17 Sep 2026
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks? - finance.yahoo.com
Wed, 09 Sep 2026
Nanobiotix (NASDAQ: NBTX) to detail nanotech pipeline at H.C. Wainwright event - Stock Titan
Fri, 17 Jul 2026
Nanobiotix (NBTX) Edges Higher Amid Support Holding – Key Levels in Focus - Leveraged ETF Flow - careplusvn.com
Wed, 15 Jul 2026
Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% Decline - VWAP Bounce - careplusvn.com
Thu, 25 Jun 2026
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform (NASDAQ:NBTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 133 (K) |
| Shares Short P.Month | 85 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.02 |
| Profit Margin | -73.6 % |
| Operating Margin | -196.5 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.64 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -55.21 |
| PEG Ratio | 0 |
| Price to Book value | -15.86 |
| Price to Sales | 49.92 |
| Price to Cash Flow | -48.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|